Tag: said-its
-
Halozyme’s pancreatic cancer drug succeeds in mid-stage trial
(Reuters) – Halozyme Therapeutics Inc said its flagship drug delivery technology in tandem with therapies from Celgene Corp and Eli Lilly and Co succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer. Shares of Halozyme were up 47.3 percent at $15.77 in trading before the opening bell on Thursday. Halozyme’s…
-
Dynavax to resubmit hep B vaccine for approval after positive data
Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration (FDA), which sought additional…
-
Dynavax to resubmit hep B vaccine for approval after positive data
Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration (FDA), which sought additional…
-
The Best Diet Ever: Three Key Ingredients
As weight loss and maintenance is one of my specialties, I am often asked, “What is the best diet?” People are often disappointed by my response. I tell them, “The best diet meets three conditions:It's a healthy diet.It's a diet that includes your favorite foods, in moderation, even if they're not entirely healthy.It's a diet…
-
UniQure shares jump on promising gene therapy data
Dutch biotech UniQure NV said its experimental gene therapy for a blood disorder benefited some patients in an early-stage study, offering a rare ray of hope in gene therapy research plagued by a series of failed trials. Janney Capital Markets analyst Debjit Chattopadhyay said UniQure’s data looked better than that of Baxalta Inc’s rival drug.…
-
Conatus liver drug shows promise in mid-stage trial
(Reuters) – Conatus Pharmaceuticals Inc said its experimental drug reduced the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial. The drug, emricasan, showed a statistically significant reduction in the protein fragment, caspase-cleaved cytokeratin 18 (cCK18), when compared with a placebo, in the overall patient population, according to the three-month…
-
Conatus liver drug shows promise in mid-stage trial
(Reuters) – Conatus Pharmaceuticals Inc said its experimental drug reduced the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial. The drug, emricasan, showed a statistically significant reduction in the protein fragment, caspase-cleaved cytokeratin 18 (cCK18), when compared with a placebo, in the overall patient population, according to the three-month…
-
Valeant plans to appoint new CEO as Pearson remains hospitalized: WSJ
(Reuters) – Valeant Pharmaceuticals International Inc is planning to appoint a new CEO as Chief Executive Michael Pearson remains hospitalized, the Wall Street Journal said, citing people familiar with the matter. The new chief executive would replace the committee currently running the company, the newspaper said. Potential new chief executive candidates include Chief Financial Officer…
-
Eli Lilly’s diabetes pill takes market share from J&J, Astra
Eli Lilly and Co’s new Jardiance diabetes treatment has begun stealing market share from rival drugs in its class, the company said on Tuesday, bolstered by clinical trial data showing it slashed deaths by 32 percent in patients with Type 2 diabetes. In a three-year study whose results were released last summer, Jardiance became the…